Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00443066 · ClinicalTrials.gov registry record

Clinical Study of Spinal Muscular Atrophy

A clinical trial of Spinal Muscular Atrophy, sponsored by Columbia University.

Completed
Registry status
120
Enrollment target
1
Study location

NCT00443066: Completed study of Spinal Muscular Atrophy, sponsored by Columbia University.

NCT00443066 is a study of Spinal Muscular Atrophy that has completed, run by Columbia University. The registered enrollment target is 120 participants, above the 104-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (15% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00443066, a study of Spinal Muscular Atrophy, has completed, sponsored by Columbia University.

COMPLETED
Registry status
120 participants
Enrollment target
1
Study location

Study Summary

The investigators propose to prepare for clinical trials where SMA patients are asked to join the research effort. The visits will include questions, physical exam, blood drawing, and sometimes X-rays and a skin biopsy. The investigators will use modern computer methods to process the information during which the investigators will plan a clinical trial. Once the clinical trial begins, the investigators will offer SMA patients participation if they meet the criteria for that trial. Identifying an effective SMA treatment is very important because there is currently none. Clinical trials are the only way to decide whether a new treatment works in SMA patients or not.

Primary Outcome

For SMAII/III patients over 2 years of age, we will additionally administer the Hammersmith SMA functional motor scale (H-SMA-FMS), a disease-specific instrument.

Conditions Studied

Study Locations (1)

New York

  • Columbia University SMA Clinical Research Center - New York

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2005-05
Est. Completion 2011-08-17
Columbia University

958 total trials

What the finished NCT00443066 record still lists

NCT00443066 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 104-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (15% higher).

The record links to 1 condition, with Spinal Muscular Atrophy appearing as the primary indexed condition, and to 0 interventions.

NCT00443066 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00443066 about?

NCT00443066 is a clinical study titled "Clinical Study of Spinal Muscular Atrophy". The investigators propose to prepare for clinical trials where SMA patients are asked to join the research effort. The visits will include questions, physical exam, blood drawing, and sometimes X-rays and a skin biopsy. The investigators will use modern computer methods to process the information du...

What is the current status of trial NCT00443066?

This trial is currently completed. The enrollment target is 120 participants. The study started on 2005-05. Estimated completion is 2011-08-17.

What conditions does trial NCT00443066 study?

This clinical trial studies the following conditions: Spinal Muscular Atrophy.

Who is sponsoring clinical trial NCT00443066?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00443066 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Muscular Atrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00443066's enrollment target sits among peer trials

120 9th of 22 higher than 14 of 22 other Spinal Muscular Atrophy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Spinal Muscular Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00443066, the US trial registry maintained by the National Library of Medicine. NCT00443066 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.